glp 1 drugs and menopause GLP-1 Medications Their Role In Weight Gain THE PCCA BLOG | Managing
Description
CNS Neurosci
Herron E, Cencetti J, Matis J
Propensity-score matching (PSM) at a 1:3 ratio between GLP1RA and DPP4i groups was done to minimise possible selection bias
Importantly, a substantial number of patients had multiple reasons noted for stopping (21%), underscoring the complexity of real-world medication use and the challenges patients face when using these therapies
38,39,40 The phenotype observed after GLP-1R knockout (KO) includes various physiological and metabolic changes
Estimated glomerular filtration rate, albuminuria, and adverse outcomes: an individual-participant data meta-analysis
